Resources Repository
-
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
Benefit-Cost Analysis | Economics/Finance | North America | Infectious Diseases | Mathematical Models | State-Transition | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Benefit-Cost Analysis | Economics/Finance | North America | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Policy/Regulation | Health/Medicine | Global -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | Economics/Finance | North America | Infectious Diseases | Value of Information | State-Transition | Policy/Regulation | Europe -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Economics/Finance | North America | Infectious Diseases | Evidence Synthesis | Cost-Effectiveness Analysis | Social Determinants | Culture/Society | Health/Medicine -
ArticlePublication 2020New Fronts in the War on Misinformation
The countless false claims that have spread alongside the novel coronavirus – inaccurate advice about …
The countless false claims that have spread alongside the novel coronavirus – inaccurate advice about how to prevent the virus, for example, and conspiracy theories about its origins – are just the latest manifestation of an ongoing problem: the online proliferation of misinformation about science and health. The National Academies hosted and helped organize three events focused on countering misinformation: The MisinfoCon conference, a Wikipedia Edit-a-thon, and a meeting to explore ways to expand successful…
Education/Labor | North America | Infectious Diseases | Decision Psychology | Preferences/Values | Social Determinants | Policy/Regulation | Culture/Society | Government/Law | Health/Medicine | Science/Technology -
Teaching PackWeb Portal, Teaching Resource 2018Teaching Pack: A Methods Sampler
This teaching pack features a collection of videos by Professor David Cutler, introducing basic concepts in …
This teaching pack features a collection of videos by Professor David Cutler, introducing basic concepts in epidemiology, economics and statistics, to support his undergraduate course, "EMR20: Why is There No Cure for Health Care?" Concept sketches, prototypes, and videos were completed and produced during Cutler's collaborative residency at the Global Health Education and Learning Incubator (GHELI).Videos include: EMR20: What is an Epidemic? (~10 min) EMR20: Dynamics of an Epidemic (~13 min) EMR20: The Economics of Pharmaceuticals, Part 1 (~20 min)…
Economics/Finance | North America | Infectious Diseases | Social Determinants | Policy/Regulation | Business/Industry | Health/Medicine | Global | High School | College | Graduate | Critical Thinking/Analysis | Quantitative Literacy -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
Economics/Finance | North America | Infectious Diseases | Evidence Synthesis | Technology Assessment | Chronic Disease/Risk | Health Systems | Policy/Regulation | Health/Medicine | Science/Technology -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Economics/Finance | North America | Infectious Diseases | Test Performance | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Health/Medicine | Global -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Economics/Finance | North America | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Government/Law | Health/Medicine | Science/Technology | Europe